Johnson & Johnson (NYSE:JNJ) is Westwood Holdings Group Inc.’s 3rd Largest Position

Westwood Holdings Group Inc. reduced its holdings in shares of Johnson & Johnson (NYSE:JNJ) by 17.2% in the second quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The fund owned 1,218,443 shares of the company’s stock after selling 252,313 shares during the period. Johnson & Johnson comprises 1.8% of Westwood Holdings Group Inc.’s portfolio, making the stock its 3rd largest holding. Westwood Holdings Group Inc.’s holdings in Johnson & Johnson were worth $169,705,000 as of its most recent SEC filing.

Several other institutional investors and hedge funds have also recently bought and sold shares of JNJ. Virtus ETF Advisers LLC bought a new position in shares of Johnson & Johnson during the second quarter worth $25,000. Krane Funds Advisors LLC purchased a new stake in Johnson & Johnson during the 2nd quarter worth about $26,000. Crewe Advisors LLC increased its position in Johnson & Johnson by 725.9% during the 2nd quarter. Crewe Advisors LLC now owns 223 shares of the company’s stock worth $31,000 after purchasing an additional 196 shares in the last quarter. Permanens Capital L.P. increased its position in Johnson & Johnson by 50.0% during the 2nd quarter. Permanens Capital L.P. now owns 300 shares of the company’s stock worth $42,000 after purchasing an additional 100 shares in the last quarter. Finally, Thor Advisors LLC purchased a new stake in Johnson & Johnson during the 1st quarter worth about $69,000. Institutional investors and hedge funds own 72.01% of the company’s stock.

NYSE:JNJ traded up $1.49 during mid-day trading on Friday, reaching $131.60. The company’s stock had a trading volume of 6,093,618 shares, compared to its average volume of 7,392,434. The company’s fifty day simple moving average is $130.02 and its two-hundred day simple moving average is $135.75. The company has a debt-to-equity ratio of 0.46, a current ratio of 1.33 and a quick ratio of 1.04. Johnson & Johnson has a twelve month low of $121.00 and a twelve month high of $148.99. The stock has a market cap of $342.22 billion, a P/E ratio of 16.09, a P/E/G ratio of 2.19 and a beta of 0.68.

Johnson & Johnson (NYSE:JNJ) last issued its quarterly earnings results on Tuesday, July 16th. The company reported $2.58 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $2.42 by $0.16. Johnson & Johnson had a return on equity of 38.63% and a net margin of 20.08%. The firm had revenue of $20.56 billion for the quarter, compared to analyst estimates of $20.39 billion. During the same period last year, the company earned $2.10 EPS. The firm’s quarterly revenue was down 1.3% on a year-over-year basis. Sell-side analysts expect that Johnson & Johnson will post 8.6 EPS for the current fiscal year.

The firm also recently declared a quarterly dividend, which was paid on Tuesday, September 10th. Shareholders of record on Tuesday, August 27th were paid a $0.95 dividend. This represents a $3.80 dividend on an annualized basis and a yield of 2.89%. The ex-dividend date of this dividend was Monday, August 26th. Johnson & Johnson’s payout ratio is 46.45%.

A number of research firms recently commented on JNJ. Zacks Investment Research cut Johnson & Johnson from a “buy” rating to a “hold” rating and set a $139.00 price objective for the company. in a research report on Thursday, July 18th. Credit Suisse Group set a $156.00 price objective on Johnson & Johnson and gave the stock a “buy” rating in a research report on Tuesday, August 27th. Goldman Sachs Group set a $169.00 price objective on Johnson & Johnson and gave the stock a “buy” rating in a research report on Tuesday, August 27th. Barclays began coverage on Johnson & Johnson in a research report on Friday, June 21st. They set a “hold” rating and a $140.00 price objective for the company. Finally, Morgan Stanley reiterated an “equal weight” rating and set a $145.00 price objective on shares of Johnson & Johnson in a research report on Tuesday, August 27th. Five equities research analysts have rated the stock with a hold rating and eight have assigned a buy rating to the company’s stock. The company has a consensus rating of “Buy” and a consensus price target of $150.60.

Johnson & Johnson Company Profile

Johnson & Johnson, together with its subsidiaries, researches and develops, manufactures, and sells various products in the health care field worldwide. It operates in three segments: Consumer, Pharmaceutical, and Medical Devices. The Consumer segment offers baby care products under the JOHNSON'S brand; oral care products under the LISTERINE brand; beauty products under the AVEENO, CLEAN & CLEAR, DABAO, JOHNSON'S Adult, LE PETITE MARSEILLAIS, NEUTROGENA, and OGX brands; over-the-counter medicines, including acetaminophen products under the TYLENOL brand; cold, flu, and allergy products under the SUDAFED brand; allergy products under the BENADRYL and ZYRTEC brands; ibuprofen products under the MOTRIN IB brand; and acid reflux products under the PEPCID brand.

Read More: Do closed-end mutual funds pay dividends?

Want to see what other hedge funds are holding JNJ? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Johnson & Johnson (NYSE:JNJ).

Institutional Ownership by Quarter for Johnson & Johnson (NYSE:JNJ)

Receive News & Ratings for Johnson & Johnson Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Johnson & Johnson and related companies with MarketBeat.com's FREE daily email newsletter.